Nausea: The neglected symptom?

European Journal of Oncology Nursing

Volumn 9, Issue 1, 2005, Pages 21-32

  Foubert, Jan ^a   Vaessen, Giel ^b,c  

^a Erasmus Hogeschool   (Belgium)

^b Bu Contracting Welzijn en Zorg ^*  (Netherlands)

^c ZUYD UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

Author keywords

5 HT3 receptor antagonist; Granisetron; Nausea; Ondansetron; Vomiting

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; GRANISETRON; HYPNOTIC AGENT; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON;

ACUTE DISEASE; AMNESIA; ANTICIPATION; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; MEDICAL STAFF; NAUSEA; NAUSEA AND VOMITING; NURSE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RADIATION INDUCED EMESIS; RADIATION SICKNESS; REVIEW; RISK ASSESSMENT; SELF REPORT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT PLANNING;

EID: 14944343578     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejon.2004.03.006     Document Type: Article

References (60)

1. 3 receptor antagonists. Cancer Today (Suppl. 1), 3-15.
2. Andrews P.L.R. Davis C.J. The mechanism of emesis induced by anti-cancer agent therapies In: Andrews P.L.R. Sanger G.J. (Eds.), Emesis in Anti-cancer Therapy 1993 113-161 Chapman and Hall London
3. Anzemet® tablets (dolasetron mesylate) Prescribing Information, 2000. Aventis Pharmaceuticals, Kansas City, MO.
4. Aprepitant FDA advisory committee background package, March 6, 2003. http://fda.gov/ohrms/dockets/ac/03/briefing/3928b1.htm
5. ASHP, 1999. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. American Journal of Health-System Pharmacy 56, 729-764.
6. Bilgrami S. Fallon B.G. Chemotherapy-induced nausea and vomiting. Easing patients' fear and discomfort with effective antiemetic regimens Postgraduate Medicine 94 1993 55-64
7. Bloomer J.C. Baldwin S.J. Smith G.J. Ayrton A.D. Clarke S.E. Chenery R.J. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron British Journal of Clinical Pharmacology 38 1994 557-566
8. 3-receptor antagonists and the cytochrome P450 system: Clinical implications Cancer Journal 8 2002 405-414
9. Carmichael J. Keizer H.J. Cupissol D. Milliez J. Scheidel P. Schindler A.E. Use of granisetron in patients refractory to previous treatment with antiemetics Anticancer Drugs 9 1998 381-385
10. Coates A. Abraham S. Kaye S.B. Sowerbutts T. Frewin C. Fox R.M. Tattersall M.H. On the receiving end - patient perception of the side-effects of cancer chemotherapy European Journal of Cancer and Clinical Oncology 19 1983 203-208
11. Danjoux C.E. Rider W.D. Fitzpatrick P.J. The acute radiation syndrome. A memorial to William Michael Court-Brown Clinical Radiology 30 1979 581-584
12. de Boer-Dennert M. de Wit R. Schmitz P.I. Djontono J. Beurden V. Stoter G. Verweij J. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists British Journal of Cancer 76 1997 1055-1061
13. de Wit R. de Boer A.C. Linden G.H.M. Stoter G. Sparreboom A. Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 h following highly emetogenic chemotherapy British Journal of Cancer 85 2001 1099-1101 (DOI:10.1054/bjoc.2001.2045)
14. 1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy Proceedings of the American Society of Clinical Oncology 22 2003 739 (Abstract 2973)
15. Dibble S.L. Israel J. Nussey B. Casey K. Luce J. Delayed chemotherapy-induced nausea in women treated for breast cancer Oncology Nursing Forum 30 2003 40-47
16. Dixon C.M. Colthup P.V. Serabjit-Singh C.J. Kerr B.M. Boehlert C.C. Park G.R. Tarbit M.H. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans Drug Metabolism and Disposition 23 1995 1225-1230
17. Doherty K.M. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy Clinical Journal of Oncology Nursing 3 1999 113-119
18. Eckert R.M. Continuing education. Understanding anticipatory nausea Oncology Nursing Forum 28 2001 1553-1560
19. Eisenberg P.D. Rubenstein E.B. Cohen L. De Moor C. Kim Y.J. Grunberg S.M. Perceptions and satisfaction (S) of oncologists (MDs) and oncology nurses (RNs) of antiemetic therapy (AET) for chemotherapy-induced nausea and vomiting (CINV) vs patient experiences after emetogenic chemotherapy (CT) in the US Proceedings of the American Society of Clinical Oncology 22 2003 740 (Abstract 2974)
20. Feyer P. Seegenschmiedt M.H. Steingräber M. Antiemetic patterns of care for radiotherapy-induced nausea and vomiting European Journal of Cancer 1S 5 2003 S29 (Abstract 929)
21. Gandara D.R. Roila F. Warr D. Edelman M.J. Perez E.A. Gralla R.J. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration Supportive Care in Cancer 6 1998 237-243
22. Gebbia V. Cannata G. Testa A. Curto G. Valenza R. Cipolla C. Latteri M.A. Gebbia N. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting Cancer 74 1994 1945-1952
23. Goedhals L. Heron J.-F. Kleisbauer J.-P. Pagani O. Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study Annals of Oncology 9 1998 661-666
24. Goldsmith B. Antiemetic patterns of care for radiotherapy-induced nausea and vomiting Proceedings of the American Society of Clinical Oncology 22 2003 740 (Abstract 2975)
25. Gralla R.J. Navari R.M. Hesketh P.J. Popovic W. Strupp J. Noy J. Einhorn L. Ettinger D. Bushnell W. Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy Journal of Clinical Oncology 16 1998 1568-1573
26. Gralla R.J. Osoba D. Kris M.G. Kirkbride P. Hesketh P.J. Chinnery L.W. Clark-Snow R. Gill D.P. Groshen S. Grunberg S. Koeller J.M. Morrow G.R. Perez E.A. Silber J.H. Pfister D.G. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines Journal of Clinical Oncology 17 1999 2971-2994
27. Gralla R. Lichinitser M. Van Der Vegt S. Sleeboom H. Mezger J. Peschel C. Tonini G. Labianca R. Macciocchi A. Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Annals of Oncology 14 2003 1570-1577
28. Griffin A.M. Butow P.N. Coates A.S. Childs A.M. Ellis P.M. Dunn S.M. Tattersall M.H. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Annals of Oncology 7 1996 189-195
29. Grunberg, S.M., Hansen, M., Deuson, R., Marvos, P., 2002. Incidence and impact of nausea/vomiting with modern antiemetics: Perception vs reality. Proceedings of the American Society of Clinical Oncology (Abstract 996)
30. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting Cancer Investigation 18 2000 163-173
31. Hesketh P.J. Kris M.G. Grunberg S.M. Beck T. Hainsworth J.D. Harker G. Aapro M.S. Gandara D. Lindley C.M. Proposal for classifying the acute emetogenicity of cancer chemotherapy Journal of Clinical Oncology 15 1997 103-109
32. Hesketh P.J. Van Belle S. Aapro M. Tattersall F.D. Naylor R.J. Hargreaves R. Carides A.D. Evans J.K. Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists European Journal of Cancer 39 2003 1074-1080
33. Italian Group For Antiemetic Research, 2004. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. Journal of Clinical Oncology 15, 725-729.
34. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced nausea and vomiting European Journal of Cancer 33 1997 66-74
35. Jenns K. Importance of nausea Cancer Nursing 17 1994 488-493
36. Kaiser R. Sezer O. Papies A. Bauer S. Schelenz C. Tremblay P.B. Possinger K. Roots I. Brockmoller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes Journal of Clinical Oncology 20 2002 2805-2811
37. Koeller J.M. Aapro M.S. Gralla R.J. Grunberg S.M. Hesketh P.J. Kris M.G. Clark-Snow R.A. Antiemetic guidelines: Creating a more practical treatment approach Journal of Supportive Care 10 2002 514-522 (DOI: 10.1007/s00520-001-0335-y)
38. Kris M.G. Gralla R.J. Tyson L.B. Clark R.A. Cirrincione C. Groshen S. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin Journal of Clinical Oncology 7 1989 108-114
39. Kytril® (granisetron hydrochloride). Prescribing information, 2000. Roche Laboratories Inc., Nutley, NJ.
40. Laszlo J. Nausea and vomiting as major complications of cancer therapy Drugs 25 1983 1-7
41. 3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin Oncology Reports 5 1998 273-280
42. Multinational Association of Supportive Care in Cancer (MASCC), 1998. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Annals of Oncology 9, 811-819.
43. National Comprehensive Cancer Network (NCCN), 1997. NCCN Antiemesis Practice Guidelines. National Comprehensive Cancer Network Proceedings 11, 57-89.
44. Navoban® (tropisetron) Product Information, 1997. Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW.
45. O'Brien B.J. Rusthoven J. Rocchi A. Latreille J. Fine S. Vandenberg T. Laberge F. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres Canadian Medical Association Journal 149 1993 296-302
46. Osoba D. Zee B. Warr D. Latreille J. Kaizer L. Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group Supportive Care in Cancer 5 1997 307-313
47. Perez E.A. Hesketh P. Sandbach J. Reeves J. Chawla S. Markman M. Hainsworth J. Bushnell W. Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study Journal of Clinical Oncology 16 1998 754-760
48. Redmond K. Advances in supportive care European Journal of Cancer Care 5 Suppl. 2 1996 1-7
49. Rhodes V.A. Criteria for assessment of nausea, vomiting and retching Oncology Nursing Forum 24 Suppl. 7 1997 13-19
50. Rhodes V.A. McDaniel R.W. The index of nausea, vomiting, and retching: A new format of the index of nausea and vomiting Oncology Nursing Forum 26 1999 889-894
51. Rhodes V.A. McDaniel R.W. Nausea, vomiting, and retching: Complex problems in palliative care CA: A Cancer Journal for Clinicians 51 2001 232-248
52. Roila F. Ciccarese G. Palladino M.A. De Angelis V. Prevention of radiotherapy-induced emesis Tumori 84 1998 274-278
53. Rutqvist L.E. Lax I. Fornander T. Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer International Journal of Radiation Oncology 22 1992 887-896
54. Schnell F.M. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control Oncologist 8 2003 187-198
55. Spector J.I. Lester E.P. Chevlen E.M. Sciortino D. Harvey J.H. Whaley W. Madajewicz S. Isaacs R. Homesley H.D. Yee S. Beck T.M. Tchekmedyian N.S. Crawford K.H. Ames M. Creed M.R. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy Oncologist 3 1998 432-438
56. Sussman N. Reactions of patients to the diagnosis and treatment of cancer Anticancer Drugs 6 Suppl. 1 1995 4-8
57. Thongprasert S. Efficacy and tolerability of tropisetron in the prevention of cisplatin-induced nausea and vomiting in advanced non-small-cell lung cancer Acta Oncologica 39 2000 221-224
58. Vaessen, G., 2002. Optimizing antiemetic treatment-nurse survey results. Presented: 3rd European Oncology Nursing Society Spring Convention, Venice, Italy, 3-11 April 2002
59. Yancik R. Ries L.A. Aging and cancer in America. Demographic and epidemiologic perspectives Hematology Oncology Clinics of North America 14 2000 17-23
60. Zofran® tablets (ondansetron hydrochloride) Product Information, 2001. Glaxo Wellcome Inc., Research Triangle Park, NC.